Effect of maternal fluoxetine exposure on lung, heart and kidney development in rat neonates

Document Type : Original Article


1 Department of Anatomy, School of Medicine; Physiology-Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

2 Department of Physiology-Pharmacology, School of Medicine; Physiology-Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran


Objective(s): Depression during pregnancy negatively affects fetal development. Fluoxetine as a selective serotonin reuptake inhibitor (SSRIs) is used for treatment of gestational depression. This study is trying to determine the effects of fluoxetine on the renal, heart and lung development.
Materials and Methods: Fifteen pregnant rats were treated with fluoxetine at 7 mg/kg from days 0 to 21 of gestation. Immediately after born, heart and kidney samples were evaluated for genes expression and histological assessment. Lung sample were fixed for immunohistochemical study.
Results: The gene expression of BMP7 and WNT4 were reduced in the kidney of fluoxetine-treated group (P-value<0.05), but in the heart of both groups no significant difference was found in gene expression (P-value>0.05). Histological assessment showed that the glomeruli of the kidneys in treated group are more primordial compared to control. There was a developmental deficiency in Bowman’s capsule, and the capsular space was not clear. The arrangements of the filaments, the position of the nucleus and cells morphology were normal in the hearts of both groups. Immunohistochemical analysis demonstrated that in the fluoxetine-exposed group HoxB5 is more expressed in the mesenchymal cells, but in the control group the expression is limited to alveolar cells.
Conclusion: According to developmental changes in kidney, heart and lung, fluoxetine affects neonatal growth during pregnancy, which may lead to delay of some organs growth. So, it is essential to survey the roles of antidepressant drugs on fatal and neonatal development during pregnancy.


Main Subjects

1. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103:698-709.
2. Alder J, Fink N, Bitzer J, Hosli I, Holzgreve W. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007; 20:189-209.
3. Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005; 51:1087-1093.
4. Chatillon O, Even C. [Antepartum depression: prevalence, diagnosis and treatment]. Encephale 2010; 36:443-451.
5. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015.
6. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293:2372-2383.
7. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156:1129-1132.
8. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158:312-316.
9. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898-906.
10. Wemakor A, Casson K, Garne E, Bakker M, Addor MC, Arriola L, et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol 2015; 30:1187-1198.
11. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91:142-152.
12. Ban L, Gibson JE, West J, Fiaschi L, Sokal R, Smeeth L, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG 2014; 121:1471-1481.
13. Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc 2015; 4:e001681.
14. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118:111-120.
15. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012; 2:e001148.
16. Matsumoto H. Hyponatremia associated with selective serotonin reuptake inhibitors. Intern Med 2005; 44:173-174.
17. Shakibaei F, Gholamrezaei A, Alikhani M, Talaeizadeh K. Serum sodium changes in fluoxetine users at different age groups. Iran J Psychiatry 2010; 5:113-116.
18. Viramontes TS, Truong H, Linnebur SA. Antidepressant-Induced Hyponatremia in Older Adults. Consult Pharm 2016; 31:139-150.
19. Carvalho AF SM, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016; 85:270-288.
20. Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, et al. Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine. J Toxicol Clin Toxicol 1997; 35:93-95.
21. ten Holt WL, van Iperen CE, Schrijver G, Bartelink AK. Severe hyponatremia during therapy with fluoxetine. Arch Intern Med 1996; 156:681-682.
22. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003; 17:471-503.
23. Moyses ZP, Nakandakari FK, Magaldi AJ. Fluoxetine effect on kidney water reabsorption. Nephrol Dial Transplant 2008; 23:1173-1178.
24. Taghizadeh R, Taghipour Z, Karimi A, Shamsizadeh A, Taghavi MM, Shariati M, et al. The expression of HoxB5 and SPC in neonatal rat lung after exposure to fluoxetine. Drug Des Devel Ther 2016; 10:3323-3329.
25. Zhu H. Forkhead box transcription factors in embryonic heart development and congenital heart disease. Life Sci 2016; 144:194-201.
26. Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol 2001; 11:1805-1809.
27. Lechner MS, Dressler GR. The molecular basis of embryonic kidney development. Mech Dev 1997; 62:105-120.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-1108.
29. Marcotte M, Sharma R, Bouchard M. Gene regulatory network of renal primordium development. Pediatr Nephrol 2014; 29:637-644.
30. Diav-Citrin O, Ornoy A. Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat? Obstet Gynecol Int 2012; 2012:698947.
31. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79:301-308.
32. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723-1733.
33. Knudsen TM, Hansen AV, Garne E, Andersen AM. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy--an epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth 2014; 14:333.
34. Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis. Daru 2012; 20:75.
35. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339:b3569.
36. Nembhard WN, Tang X, Hu Z, MacLeod S, Stowe Z, Webber D, et al. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. BMJ 2017; 356:j832.
37. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015; 350:h1798.
38. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, National Birth Defects Prevention S. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 2015; 351:h3190.
39. Daud AN, Bergman JE, Kerstjens-Frederikse WS, Groen H, Wilffert B. The risk of congenital heart anomalies following prenatal exposure to serotonin reuptake inhibitors-is pharmacogenetics the Key? Int J Mol Sci 2016; 17:1333.
40. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010; 2:29-36.
41. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88:94-100.
42. Velasquez JC, Goeden N, Bonnin A. Placental serotonin: implications for the developmental effects of SSRIs and maternal depression. Front Cell Neurosci 2013; 7:47.
43. Kaihola H, Yaldir FG, Hreinsson J, Hornaeus K, Bergquist J, Olivier JD, et al. Effects of fluoxetine on human embryo development. Front Cell Neurosci 2016; 10:160.